TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25986629
Drug: Threshold suspend
Normalized name: SUSPENDING VEHICLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Threshold suspend (TS) feature of sensor-augmented insulin pump (SAP) therapy
Study: 25987537
Drug: Intravenous immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulins (IVIG) as an adjunct to standard treatment
Study: 25987620
Drug: Cycloserine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycloserine (250 mg), p-aminosalicylic acid (PAS) (5.28 g), prothionamide (250 mg) twice daily, pyrazinamide (1,500 mg) once daily, levofloxacin (750 mg) once daily, streptomycin (1 g) once daily
Study: 25987620
Drug: Cycloserine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycloserine (250 mg), p-aminosalicylic acid (PAS) (5.28 g), prothionamide (250 mg) twice daily, pyrazinamide (1,500 mg) once daily, moxifloxacin (400 mg) once daily, kanamycin (1 g) once daily
Study: 25987791
Drug: Cholecalciferol 100000
Normalized name: cholecalciferol 100000 UNT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 100000 IU per week for 4 weeks followed by 100000 IU per month in combination with PegIFN/RBV for 12 months.
Study: 25988359
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) with clopidogrel
Study: 25989179
Drug: White button
Normalized name: button mushroom extract
DrugBank: Cultivated mushroom (DB10544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White button mushroom (WBM) powder, dosage of 8 g/d and 14 g/d
Study: 25989829
Drug: Etravirine (ETR)
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Etravirine (ETR) 400 mg for 8 weeks after switching from bPI or EFV
Study: 25989973
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of FSFI during menstruation
Study: 25989973
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of FSFI between menses
Study: 25990577
Drug: LNG-IUS 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG-IUS 52 mg
Study: 25991083
Drug: Faldaprevir 80
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 80 mg q.d. + deleobuvir 600 mg b.i.d. + weight-based ribavirin
Study: 25991083
Drug: Faldaprevir 120
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 120 mg q.d. + deleobuvir 600 mg b.i.d. + weight-based ribavirin
Study: 25993630
Drug: L-Arginine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Arginine therapy (single dose and 6-week steady-state trial)
Study: 25994816
Drug: Variant rs11668344-G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variant rs11668344-G
Study: 25995313
Drug: High-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aspirin (325 mg)
Study: 25998039
Drug: ACE inhibitors/angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors/angiotensin receptor blockers
Study: 25998042
Drug: Foretinib (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foretinib (various formulations including bisphosphate salt capsules, freebase tablets, and solution formulation)
Study: 25998042
Drug: Foretinib (solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foretinib (solution formulation)
Study: 25998717
Drug: Robot-assisted gait
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted gait therapy with the Lokomat® system (Intervention group, IG)
Study: 25999106
Drug: iFR outside
Approvals — FDA: no, EMA: no, PMDA: no
Description: iFR outside of treatment (≤0.85) and deferral (≥0.94) values
Study: 25999183
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 325 mg pretreatment
Study: 25999183
Drug: Slow dose
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow dose titration DMF
Study: 25999435
Drug: Lenalidomide 10
Normalized name: lenalidomide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 10 mg (cohort 1)
Study: 25999435
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg (cohorts 2 and 3)
Study: 25999435
Drug: IPH2101 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPH2101 0.2 mg/kg (cohort 1)
Study: 25999435
Drug: IPH2101 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPH2101 1 mg/kg (cohort 2)
Study: 25999435
Drug: IPH2101 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPH2101 2 mg/kg (cohort 3)
Study: 25999435
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Lenalidomide and IPH2101
Study: 25999444
Drug: Ruxolitinib, specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib, specific dosage and duration not available
Study: 26001793
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events related to treatments including recombinant activated factor VII
Study: 26003007
Drug: Regorafenib 60
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 60 mg/d continuously, Cisplatin 75 mg/m², Pemetrexed 500 mg/m² once every 21 days for up to 6 cycles.
Study: 26006067
Drug: Carboplatin AUC
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 6 iv every 21 days and eribulin 1.4 mg/m2 on day 1 and day 8 every 21 days for four cycles
Study: 26009269
Drug: Saracatinib 175mg
Normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saracatinib 175mg orally daily
Study: 26009994
Drug: siG12D-LODER™ plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: siG12D-LODER™ plus chemotherapy
Study: 26010778
Drug: HAI and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAI and systemic chemotherapy
Study: 26011265
Drug: High Clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Clopidogrel dose
Study: 26014957
Drug: Single-dose doripenem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose doripenem (5 mg/kg for <8 weeks and 8 mg/kg for ≥8 weeks) administered intravenously over 1 h
Study: 26014957
Drug: Single-dose doripenem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose doripenem
Study: 26015411
Drug: Oseltamivir 3
Normalized name: oseltamivir 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 3 mg/kg (cohort 1)
Study: 26015411
Drug: Oseltamivir 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 2.5 mg/kg (cohort 2)
Study: 26015411
Drug: Oseltamivir 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 2 mg/kg (cohort 3)
Study: 26018967
Drug: DFMO (difluoromethylornithine)
Normalized name: DFMO
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DFMO (difluoromethylornithine) 500-1500 mg/m2 orally twice a day for three weeks, followed by DFMO plus daily oral etoposide for additional three-week cycles.
Study: 26020101
Drug: PHiD-CV (10-valent
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHiD-CV (10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine)
Study: 26020125
Drug: Ceritinib 300
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ceritinib 300 to 750 mg once daily in 21-day cycles
Study: 26020125
Drug: Ceritinib 750
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ceritinib 750 mg once daily (maximum-tolerated dose)
Study: 26020762
Drug: Quantitative Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quantitative Insulin Sensitivity Check Index (as a surrogate for hepatic insulin sensitivity)
Study: 26020806
Drug: Cabazitaxel 20
Normalized name: cabazitaxel 20 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel 20 mg/m plus Gemcitabine 1000 mg/m
Study: 26020806
Drug: Cabazitaxel 15
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel 15 mg/m plus Gemcitabine 900 mg/m
Study: 26020806
Drug: Cabazitaxel 15
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel 15 mg/m plus Gemcitabine 700 mg/m
Study: 26020806
Drug: Gemcitabine 700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 700 mg/m followed by Cabazitaxel 15 mg/m
Study: 26020806
Drug: Cabazitaxel plus
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel plus Gemcitabine (all doses)
Study: 26024531
Drug: MiCK drug-induced
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MiCK drug-induced apoptosis assay (used by physicians)
Study: 26025572
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg od
Study: 26025807
Drug: 4CMenB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB vaccine administered at 0, 2, and 6 months
Study: 26025807
Drug: ACWY-CRM vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACWY-CRM vaccine administered concomitantly at 0 months
Study: 26025933
Drug: Bevacizumab (BV)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (BV) at 10 mg/kg every 2 weeks, Temozolomide (TMZ) at 200 mg/m² per day on days 1-5, Irinotecan (CPT-11) at 125 mg/m² or 340 mg/m² every 2 weeks depending on antiepileptic drugs.
Study: 26025965
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg daily and Everolimus 5 mg daily until disease progression, intolerable toxicity, investigator or patient decision.
Study: 26026738
Drug: hu3S193 (20mg/m²
Approvals — FDA: no, EMA: no, PMDA: no
Description: hu3S193 (20mg/m² intravenously weekly for 8 weeks, up to 3 cycles)
Study: 26028255
Drug: Pembrolizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (10 mg/kg every 14 days) in mismatch repair-deficient colorectal cancers
Study: 26028255
Drug: Pembrolizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (10 mg/kg every 14 days) in mismatch repair-proficient colorectal cancers
Study: 26028255
Drug: Pembrolizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (10 mg/kg every 14 days) in mismatch repair-deficient non-colorectal cancers
Study: 26028965
Drug: Anagrelide therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anagrelide therapy in JAK2-positive patients
Study: 26028965
Drug: Anagrelide therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anagrelide therapy in JAK2-negative patients
Study: 26028965
Drug: Anagrelide therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anagrelide therapy in JAK2-positive patients (last observation carried forward)
Study: 26028965
Drug: Anagrelide therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anagrelide therapy in JAK2-negative patients (last observation carried forward)
Study: 26031269
Drug: Preincision gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preincision gentamicin injection
Study: 26033282
Drug: CBD 300
Normalized name: MENTHOL, UNSPECIFIED FORM 10 g in 100 g / CAMPHOR (SYNTHETIC) 3 g in 100 g TOPICAL CREAM [ETERNAL SPIRIT BEAUTY PAINLESS WITH CBD 3000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD 300 mg/day given orally starting 7 days before transplantation until day 30
Study: 26037794
Drug: Implantable cardioverter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy-defibrillator (CRT-D) implant
Study: 26038709
Drug: Troponin T
Normalized name: Troponin T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troponin T > 0.05 ng/mL
Study: 26040252
Drug: Mobile app
Normalized name: Mahana IBS CBT Mobile Application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile app follow-up care using QoR9, VAS, surgery-specific questions, and surgical site photos submitted daily for the first 2 weeks and weekly for the following 2 weeks.
Study: 26040622
Drug: Ixabepilone (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixabepilone (6 mg/m² per day for 5 days every 21 days)
Study: 26040640
Drug: Mathematical model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mathematical model of human metabolism
Study: 26041763
Drug: Aplidin 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aplidin 5 mg/m(2) days 1-15, 28-day cycle until disease progression or unacceptable toxicity
Study: 26043810
Drug: velaglucerase alfa
Normalized name: Velaglucerase alfa
DrugBank: Velaglucerase alfa (DB06720)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: velaglucerase alfa 30-60U/kg by intravenous infusion every other week
Study: 26044316
Drug: Magnetic sphincter
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetic sphincter augmentation device
Study: 26046067
Drug: Intratumoral injection
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral injection of Clostridium novyi-NT spores
Study: 26048686
Drug: High caloric
Normalized name: high caloric supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: High caloric (428 kcal) (13)C-Sodium Octanoate breath test OFF dopaminergic medication
Study: 26048686
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral Levodopa/25 mg Benserazide
Study: 26049121
Drug: Intraperitoneal catumaxomab
Normalized name: catumaxomab
DrugBank: Catumaxomab (DB06607)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal catumaxomab infusion
Study: 26049781
Drug: 2 μg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg/mL TCI propofol
Study: 26049781
Drug: 3 μg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 μg/mL TCI propofol
Study: 26049781
Drug: 4 μg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 μg/mL TCI propofol
Study: 26049896
Drug: Olipudase alfa
Normalized name: OLIPUDASE ALFA
DrugBank: Olipudase alfa (DB12835)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olipudase alfa (0.1 to 3.0 mg/kg, intravenously every 2 weeks for 26 weeks)
Study: 26053994
Drug: General anaesthetic
Normalized name: General anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthetic agents (halogenated agents or propofol)
Study: 26059242
Drug: Bone marrow-derived
Normalized name: Allogeneic human bone marrow-derived mpc
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow-derived mononuclear cells (BMDMCs) administered through bronchoscopy (2 × 10(7) cells)
Study: 26059948
Drug: Ibrutinib 560
Normalized name: ibrutinib 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 560 mg once daily
Study: 26062135
Drug: Imaginal exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaginal exposure for PTSD with dialectical behavior therapy
Study: 26062823
Drug: Anaplastic lymphoma
Normalized name: Anaplastic lymphoma kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaplastic lymphoma kinase (ALK) inhibitor (crizotinib/Xalkori®) and a multikinase VEGF inhibitor (pazopanib/Votrient®)
Study: 26063065
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g tomato puree providing 0.4 mg β-carotene
Study: 26063065
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 25 SNPs in 12 genes
Study: 26063067
Drug: B vitamin-containing
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B vitamin-containing supplements
Study: 26063483
Drug: Birth preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birth preparation
Study: 26063633
Drug: Pazopanib as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib as a single agent
Study: 26064113
Drug: 2-week continuous
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week continuous administration of a protein-based formula (1.2 g/kg of ideal body weight/day) by nasogastric tube
Study: 26064113
Drug: 2-week continuous
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week continuous administration of a protein-based formula
Study: 26064192
Drug: semagacestat (γ-secretase
Approvals — FDA: no, EMA: no, PMDA: no
Description: semagacestat (γ-secretase inhibitor)
Study: 26065566
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (adenotonsillectomy)
Study: 26065566
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (non-OSAS)
Study: 26065566
Drug: RDI at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RDI at T0 and increase in BMI as risk factors for persistent OSAS in dietary treatment
Study: 26065651
Drug: Nilotinib plus
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib plus multiagent chemotherapy (vincristine, daunorubicin, prednisolone) during induction treatment
Study: 26065651
Drug: Nilotinib plus
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib plus multiagent chemotherapy
Study: 26065651
Drug: Nilotinib combined
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib combined with high-dose cytotoxic drugs
Study: 26066765
Drug: Romiplostim treatment
Normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Romiplostim treatment for up to 4 years
Study: 26069234
Drug: Circulating FABP4
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Circulating FABP4 in patients with ST-segment-elevation myocardial infarction (24.9 ng/mL)
Study: 26070683
Drug: Dovitinib (TKI258),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dovitinib (TKI258), 500mg orally once daily for five consecutive days, followed by a 2-day rest every week
Study: 26071053
Drug: R-CHOP treatment
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP treatment (rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone) followed by two cycles of R (R-CHOP-14)
Study: 26071053
Drug: R-CHOP treatment
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP treatment
Study: 26071868
Drug: Vorinostat (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorinostat (200 mg/day to 1000 mg/day, days -8 to -3) + Gemcitabine (10 mg/m²/minute over 4.5 hours, days -8 and -3) + Busulfan (targeted 4000 μM-minute/day, days -8 to -5) + Melphalan (60 mg/m²/day, days -3 and -2) + Rituximab (375 mg/m², days +1 and +8 for CD20(+) tumors)
Study: 26072149
Drug: Daptomycin at
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin at 4 mg/kg/day
Study: 26072932
Drug: 5-Ling Granule
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Ling Granule (15-22.5 g/day)
Study: 26072932
Drug: Tiapride (200-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapride (200-400 mg/day)
Study: 26073352
Drug: Alisertib oral
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib oral solution (OS) 25 mg
Study: 26073352
Drug: Alisertib powder-in-capsule
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib powder-in-capsule (PIC) 50 mg
Study: 26073352
Drug: Alisertib oral
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib oral solution (OS)
Study: 26073352
Drug: Alisertib powder-in-capsule
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib powder-in-capsule (PIC)
Study: 26073451
Drug: KRN23 (0.05,
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRN23 (0.05, 0.10 ± 0.01, 0.28 ± 0.06, and 0.48 ± 0.16 mg/kg administered subcutaneously every 28 days)
Study: 26075081
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of phylloquinone three times per week
Study: 26075081
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration three times per week
Study: 26075496
Drug: Novel TNXB
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel TNXB missense variant c.12174C>G (p.C4058W)
Study: 26077240
Drug: Alisertib 50
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib 50 mg twice a day for 7 days on 21-day cycles
Study: 26077415
Drug: Antihistamine premedication
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine premedication
Study: 26077415
Drug: Concomitant immunosuppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant immunosuppressant or corticosteroids
Study: 26077415
Drug: Antihistamines, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamines, intravenous steroids, and acetaminophen as preventative premedication
Study: 26079776
Drug: Short-term Intensive
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term Intensive Insulin Therapy (IIT) for 4 weeks, consisting of basal detemir and premeal insulin aspart.
Study: 26082332
Drug: Onalespib (AT13387)
Normalized name: Onalespib
DrugBank: Onalespib (DB06306)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onalespib (AT13387) at RP2D of 160 mg/m(2)/dose administered on days 1, 2, 8, 9, 15, and 16 of 28 day cycles (QDx2/week)
Study: 26082464
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of virulent S. Paratyphi A bacteria (NVGH308 strain) with a bicarbonate buffer solution to establish the infectious dose.
Study: 26082815
Drug: Oral levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral levosimendan (0.125 to 2.0 mg daily for 18-day intervals)